2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Journal of the American College of Cardiology

Volumn 73, Issue 24, 2019, Pages 3168-3209

  Grundy, Scott M ^a   Stone, Neil J ^a   Bailey, Alison L ^a   Beam, Craig ^a   Birtcher, Kim K ^a   Blumenthal, Roger S ^a   Braun, Lynne T ^a   de Ferranti, Sarah ^a   Faiella Tommasino, Joseph ^a   Forman, Daniel E ^a   Goldberg, Ronald ^a   Heidenreich, Paul A ^a   Hlatky, Mark A ^a   Jones, Daniel W ^a   Lloyd Jones, Donald ^a   Lopez Pajares, Nuria ^a   Ndumele, Chiadi E ^a   Orringer, Carl E ^a   Peralta, Carmen A ^a   Saseen, Joseph J ^a   Smith, Sidney C ^a   Sperling, Laurence ^a   Virani, Salim S ^a   Yeboah, Joseph ^a   more..

^a NONE

Author keywords

ACC AHA Clinical Practice Guidelines; biomarkers; cardiovascular disease; cholesterol; coronary artery calcium score; diabetes mellitus; drug therapy; ezetimibe; Guidelines; hydroxymethylglutaryl CoA reductase inhibitors statins; hypercholesterolemia; LDL cholesterol; lipids; patient compliance; pharmacological; primary prevention; proprotein convertase subtilisin kexin type 9 inhibitor (PCSK9) inhibitors; risk assessment; risk reduction discussion; risk treatment discussion; secondary prevention

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; CHOLESTEROL; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PCSK9 INHIBITOR; PITAVASTATIN; PRAVASTATIN; PROPROTEIN CONVERTASE 9; ROSUVASTATIN; SERINE PROTEINASE INHIBITOR; SIMVASTATIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT; PCSK9 PROTEIN, HUMAN;

AGE DISTRIBUTION; AGING; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE MYOPATHY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CHRONIC KIDNEY FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIUM SCORE; DIABETES MELLITUS; DRUG SAFETY; ETHNICITY; FAMILIAL HYPERCHOLESTEROLEMIA; HEALTH ECONOMICS; HEALTHY LIFESTYLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIVER FAILURE; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; TREATMENT RESPONSE; BLOOD; CARDIOLOGY; CARDIOVASCULAR DISEASE; MEDICAL SOCIETY; MEDICATION THERAPY MANAGEMENT; PROCEDURES; PSYCHOLOGY; UNITED STATES;

AMERICAN HEART ASSOCIATION; ANTICHOLESTEREMIC AGENTS; BIOMARKERS; CARDIOLOGY; CARDIOVASCULAR DISEASES; EZETIMIBE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MEDICATION THERAPY MANAGEMENT; PROPROTEIN CONVERTASE 9; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; UNITED STATES;

EID: 85067085494     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.11.002     Document Type: Article

References (346)

1. Grundy, S.M., Stone, N.J., Bailey, A.L., et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73 (2019), e285–e350.
2. Wilson, P.W.F., Polonsky, T.S., Miedema, M.D., et al. Systematic review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73 (2019), 3210–3227.
3. Grundy, S.M., Stone, N.J., Bailey, A.L., et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73 (2019), e285–e350.
4. Baigent, C., Blackwell, L., Emberson, J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
5. Chou, R., Dana, T., Blazina, I., et al. Statin use for the prevention of cardiovascular disease in adults: a systematic review for the U.S. Preventive Services Task Force. 2016, U.S. Agency for Healthcare Research and Quality, Rockville, MD Report No.: 14-05206-EF-2.
6. Taylor, F., Huffman, M.D., Macedo, A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev, 2013, CD004816.
7. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
8. Halperin, J.L., Levine, G.N., Al-Khatib, S.M., et al. Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 67 (2016), 1572–1574.
9. Langsted, A., Freiberg, J.J., Nordestgaard, B.G., Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 118 (2008), 2047–2056.
10. Langsted, A., Nordestgaard, B.G., Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study. Clin Chem 57 (2011), 482–489.
11. Mora, S., Rifai, N., Buring, J.E., et al. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem 55 (2009), 888–894.
12. Sidhu, D., Naugler, C., Fasting time and lipid levels in a community-based population: a cross-sectional study. Arch Intern Med 172 (2012), 1707–1710.
13. Di Angelantonio, E., Sarwar, N., Perry, P., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302 (2009), 1993–2000.
14. Doran, B., Guo, Y., Xu, J., et al. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). Circulation 130 (2014), 546–553.
15. Martin, S.S., Blaha, M.J., Elshazly, M.B., et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol 62 (2013), 732–739.
16. Martin, S.S., Blaha, M.J., Elshazly, M.B., et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA 310 (2013), 2061–2068.
17. Sathiyakumar, V., Park, J., Golozar, A., et al. Fasting versus nonfasting and low-density lipoprotein cholesterol accuracy. Circulation 137 (2018), 10–19.
18. Miller, M., Stone, N.J., Ballantyne, C., et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123 (2011), 2292–2333.
19. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
20. Karlson, B.W., Wiklund, O., Palmer, M.K., et al. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J Cardiovasc Pharmacother 2 (2016), 212–217.
21. Naito, R., Miyauchi, K., Daida, H., Racial differences in the cholesterol-lowering effect of statin. J Atheroscler Thromb 24 (2017), 19–25.
22. Collins, R., Reith, C., Emberson, J., et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388 (2016), 2532–2561.
23. American College of Cardiology. American College of Cardiology LDL-C Manager. Available at: http://tools.acc.org/ldl. Accessed: January 8, 2018.
24. U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed January 8, 2018.
25. Ridker, P.M., Danielson, E., Fonseca, F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008), 2195–2207.
26. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994), 1383–1389.
27. Downs, J.R., Clearfield, M., Weis, S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998), 1615–1622.
28. Sacks, F.M., Pfeffer, M.A., Moye, L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996), 1001–1009.
29. Shepherd, J., Cobbe, S.M., Ford, I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995), 1301–1307.
30. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998), 1349–1357.
31. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002), 23–33.
32. Amarenco, P., Bogousslavsky, J., Callahan, A. 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006), 549–559.
33. Cannon, C.P., Braunwald, E., McCabe, C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004), 1495–1504.
34. LaRosa, J.C., Grundy, S.M., Waters, D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005), 1425–1435.
35. Nakamura, H., Arakawa, K., Itakura, H., et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368 (2006), 1155–1163.
36. Pedersen, T.R., Faergeman, O., Kastelein, J.J., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 (2005), 2437–2445.
37. Yusuf, S., Bosch, J., Dagenais, G., et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374 (2016), 2021–2031.
38. Baigent, C., Blackwell, L., Emberson, J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
39. Amarenco, P., Bogousslavsky, J., Callahan, A. 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006), 549–559.
40. Athyros, V.G., Papageorgiou, A.A., Mercouris, B.R., et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 18 (2002), 220–228.
41. Baigent, C., Blackwell, L., Emberson, J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
42. Collins, R., Reith, C., Emberson, J., et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388 (2016), 2532–2561.
43. Group HPSC. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 45 (2007), 645–654 discussion 53-4.
44. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994), 1383–1389.
45. Sacks, F.M., Pfeffer, M.A., Moye, L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996), 1001–1009.
46. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998), 1349–1357.
47. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 336 (1997), 153–162.
48. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002), 23–33.
49. Knopp, R.H., d'Emden, M., Smilde, J.G., et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29 (2006), 1478–1485.
50. Koren, M.J., Hunninghake, D.B., Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 44 (2004), 1772–1779.
51. Serruys, P.W., de Feyter, P., Macaya, C., et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287 (2002), 3215–3222.
52. Bohula, E.A., Morrow, D.A., Giugliano, R.P., et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. J Am Coll Cardiol 69 (2017), 911–921.
53. Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
54. Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
55. Giugliano, R.P., Mach, F., Zavitz, K., et al. Cognitive function in a randomized trial of evolocumab. N Engl J Med 377 (2017), 633–643.
56. Sabatine, M.S., Giugliano, R.P., Keech, A.C., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376 (2017), 1713–1722.
57. Schwartz, G.G., Steg, P.G., Szarek, M., et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379 (2018), 2097–2107.
58. Wilson, P.W.F., Polonsky, T.S., Miedema, M.D., et al. Systematic review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73 (2019), 3210–3227.
59. Hlatky, M.A., Kazi, D.S., PCSK9 inhibitors: economics and policy. J Am Coll Cardiol 70 (2017), 2677–2687.
60. Kazi, D.S., Moran, A.E., Coxson, P.G., et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA 316 (2016), 743–753.
61. Gandra, S.R., Villa, G., Fonarow, G.C., et al. Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol 39 (2016), 313–320.
62. Bellosta, S., Corsini, A., Statin drug interactions and related adverse reactions. Expert Opin Drug Saf 11 (2012), 933–946.
63. Gnjidic, D., Le Couteur, D.G., Blyth, F.M., et al. Statin use and clinical outcomes in older men: a prospective population-based study. BMJ Open, 3, 2013, e002333.
64. Gray, S.L., Boudreau, R.M., Newman, A.B., et al. Angiotensin-converting enzyme inhibitor and statin use and incident mobility limitation in community-dwelling older adults: the Health, Aging and Body Composition study. J Am Geriatr Soc 59 (2011), 2226–2232.
65. Ho, C.K., Walker, S.W., Statins and their interactions with other lipid-modifying medications: safety issues in the elderly. Ther Adv Drug Saf 3 (2012), 35–46.
66. LaCroix, A.Z., Gray, S.L., Aragaki, A., et al. Statin use and incident frailty in women aged 65 years or older: prospective findings from the Women's Health Initiative Observational Study. J Gerontol A Biol Sci Med Sci 63 (2008), 369–375.
67. Pilotto, A., Panza, F., Copetti, M., et al. Statin treatment and mortality in community-dwelling frail older patients with diabetes mellitus: a retrospective observational study. PLoS One, 10, 2015, e0130946.
68. Qi, K., Reeve, E., Hilmer, S.N., et al. Older peoples' attitudes regarding polypharmacy, statin use and willingness to have statins deprescribed in Australia. Int J Clin Pharm 37 (2015), 949–957.
69. Scott, D., Blizzard, L., Fell, J., et al. Statin therapy, muscle function and falls risk in community-dwelling older adults. Qjm 102 (2009), 625–633.
70. Thai, M., Reeve, E., Hilmer, S.N., et al. Prevalence of statin-drug interactions in older people: a systematic review. Eur J Clin Pharmacol 72 (2016), 513–521.
71. Feldman, H.H., Doody, R.S., Kivipelto, M., et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74 (2010), 956–964.
72. Houx, P.J., Shepherd, J., Blauw, G.J., et al. Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk. J Neurol Neurosurg Psychiatry 73 (2002), 385–389.
73. Rodriguez, F., Maron, D.J., Knowles, J.W., et al. Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol 2 (2017), 47–54.
74. Sano, M., Bell, K.L., Galasko, D., et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 77 (2011), 556–563.
75. Trompet, S., van Vliet, P., de Craen, A.J., et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 257 (2010), 85–90.
76. Feinstein, M.J., Jhund, P., Kang, J., et al. Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. Eur J Heart Fail 17 (2015), 434–441.
77. Bonaca, M.P., Nault, P., Giugliano, R.P., et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation 137 (2018), 338–350.
78. Besseling, J., Hovingh, G.K., Huijgen, R., et al. Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality. J Am Coll Cardiol 68 (2016), 252–260.
79. Khera, A.V., Won, H.H., Peloso, G.M., et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol 67 (2016), 2578–2589.
80. Nanchen, D., Gencer, B., Muller, O., et al. Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes. Circulation 134 (2016), 698–709.
81. Perak, A.M., Ning, H., de Ferranti, S.D., et al. Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia ohenotype. Circulation 134 (2016), 9–19.
82. Shepherd, J., Cobbe, S.M., Ford, I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995), 1301–1307.
83. Versmissen, J., Oosterveer, D.M., Yazdanpanah, M., et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ, 337, 2008, a2423.
84. Baigent, C., Blackwell, L., Emberson, J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
85. Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
86. Silverman, M.G., Ference, B.A., Im, K., et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 316 (2016), 1289–1297.
87. Kastelein, J.J., Akdim, F., Stroes, E.S., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 (2008), 1431–1443.
88. Huijgen, R., Abbink, E.J., Bruckert, E., et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther 32 (2010), 615–625.
89. Ross, S., D'Mello, M., Anand, S.S., et al. Effect of bile acid sequestrants on the risk of cardiovascular events: a Mendelian randomization analysis. Circ Cardiovasc Genet 8 (2015), 618–627.
90. Kastelein, J.J., Ginsberg, H.N., Langslet, G., et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 36 (2015), 2996–3003.
91. Perez de Isla, L., Alonso, R., Mata, N., et al. Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation 135 (2017), 2133–2144.
92. Raal, F.J., Stein, E.A., Dufour, R., et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385 (2015), 331–340.
93. Nicholls, S.J., Brandrup-Wognsen, G., Palmer, M., et al. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 105 (2010), 69–76.
94. Pedersen, S.B., Langsted, A., Nordestgaard, B.G., Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med 176 (2016), 1834–1842.
95. Colhoun, H.M., Betteridge, D.J., Durrington, P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004), 685–696.
96. Collins, R., Armitage, J., Parish, S., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003), 2005–2016.
97. de Vries, F.M., Denig, P., Pouwels, K.B., et al. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs 72 (2012), 2365–2373.
98. Knopp, R.H., d'Emden, M., Smilde, J.G., et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29 (2006), 1478–1485.
99. Mulnier, H.E., Seaman, H.E., Raleigh, V.S., et al. Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database. Diabetologia 51 (2008), 1639–1645.
100. Rana, J.S., Liu, J.Y., Moffet, H.H., et al. Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events. J Gen Intern Med 31 (2016), 387–393.
101. Sever, P.S., Poulter, N.R., Dahlof, B., et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial—lipid-lowering arm (ASCOT-LLA). Diabetes Care 28 (2005), 1151–1157.
102. Soedamah-Muthu, S.S., Fuller, J.H., Mulnier, H.E., et al. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care 29 (2006), 798–804.
103. Wong, N.D., Glovaci, D., Wong, K., et al. Global cardiovascular disease risk assessment in United States adults with diabetes. Diab Vasc Dis Res 9 (2012), 146–152.
104. Karmali, K.N., Goff, D.C. Jr, Ning, H., et al. A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol 64 (2014), 959–968.
105. Muntner, P., Colantonio, L.D., Cushman, M., et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA 311 (2014), 1406–1415.
106. Baigent, C., Blackwell, L., Emberson, J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
107. Ridker, P.M., Danielson, E., Fonseca, F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008), 2195–2207.
108. Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
109. Baigent, C., Landray, M.J., Reith, C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377 (2011), 2181–2192.
110. Brownrigg, J.R., de Lusignan, S., McGovern, A., et al. Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus. Heart 100 (2014), 1837–1843.
111. Constantino, M.I., Molyneaux, L., Limacher-Gisler, F., et al. Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care 36 (2013), 3863–3869.
112. Dabelea, D., Stafford, J.M., Mayer-Davis, E.J., et al. Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. JAMA 317 (2017), 825–835.
113. Guo, V.Y., Cao, B., Wu, X., et al. Prospective association between diabetic retinopathy and cardiovascular disease—a systematic review and meta-analysis of cohort studies. J Stroke Cerebrovasc Dis 25 (2016), 1688–1695.
114. Huo, X., Gao, L., Guo, L., et al. Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. Lancet Diabetes Endocrinol 4 (2016), 115–124.
115. Nezarat, N., Budoff, M.J., Luo, Y., et al. Presence, characteristics, and volumes of coronary plaque determined by computed tomography angiography in young type 2 diabetes mellitus. Am J Cardiol 119 (2017), 1566–1571.
116. Ogren, M., Hedblad, B., Engstrom, G., et al. Prevalence and prognostic significance of asymptomatic peripheral arterial disease in 68-year-old men with diabetes. Results from the population study ‘Men born in 1914’ from Malmo, Sweden. Eur J Vasc Endovasc Surg 29 (2005), 182–189.
117. Pambianco, G., Costacou, T., Ellis, D., et al. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 55 (2006), 1463–1469.
118. Pang, X.H., Han, J., Ye, W.L., et al. Lower extremity peripheral arterial disease is an independent predictor of coronary heart disease and stroke risks in patients with type 2 diabetes mellitus in China. Int J Endocrinol, 2017, 2017, 9620513.
119. Svensson, M.K., Cederholm, J., Eliasson, B., et al. Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. Diab Vasc Dis Res 10 (2013), 520–529.
120. Budoff, M.J., Young, R., Burke, G., et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). Eur Heart J 39 (2018), 2401–2408.
121. Avorn, J., The psychology of clinical decision making - implications for medication use. N Engl J Med 378 (2018), 689–691.
122. Lloyd-Jones, D.M., Morris, P.B., Ballantyne, C.M., et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 68 (2016), 92–125.
123. Lloyd-Jones, D.M., Morris, P.B., Ballantyne, C.M., et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 70 (2017), 1785–1822.
124. Muntner, P., Colantonio, L.D., Cushman, M., et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA 311 (2014), 1406–1415.
125. Eckel, R.H., Jakicic, J.M., Ard, J.D., et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 129 (2014), S76–S99.
126. Jensen, M.D., Ryan, D.H., Apovian, C.M., et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 63 (2014), 2985–3023.
127. U.S. Department of Health and Human Services. 2008 Physical Activity Guidelines for Americans. Available at: https://health.gov/paguidelines/pdf/paguide.pdf. Accessed August 24, 2018.
128. Estruch, R., Ros, E., Salas-Salvado, J., et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368 (2013), 1279–1290.
129. U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015–2020 Dietary Guidelines for Americans. 8th ed. December 2015. Available at: http://health.gov/dietaryguidelines/2015/guidelines/. Accessed August 24, 2018.
130. Lichtenstein, A.H., Appel, L.J., Brands, M., et al. Summary of American Heart Association diet and lifestyle recommendations revision 2006. Arterioscler Thromb Vasc Biol 26 (2006), 2186–2191.
131. Ginsberg, H.N., Kris-Etherton, P., Dennis, B., et al. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. Arterioscler Thromb Vasc Biol 18 (1998), 441–449.
132. Dehghan, M., Mente, A., Zhang, X., et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet 390 (2017), 2050–2062.
133. Chen, M., Li, Y., Sun, Q., et al. Dairy fat and risk of cardiovascular disease in 3 cohorts of US adults. Am J Clin Nutr 104 (2016), 1209–1217.
134. Loria, C.M., Liu, K., Lewis, C.E., et al. Early adult risk factor levels and subsequent coronary artery calcification: the CARDIA Study. J Am Coll Cardiol 49 (2007), 2013–2020.
135. Carr, J.J., Jacobs, D.R. Jr, Terry, J.G., et al. Association of cronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death. JAMA Cardiol 2 (2017), 391–399.
136. Choosing interventions that are cost effective (WHO-CHOICE): cost-effectiveness thresholds, 2009, World Health Organization, Geneva. Switzerland.
137. Physical Activity Guidelines Advisory Committee report, 2008. To the Secretary of Health and Human Services. Part A: executive summary. Nutr Rev 67 (2009), 114–120.
138. Warburton, D.E., Charlesworth, S., Ivey, A., et al. A systematic review of the evidence for Canada's physical activity guidelines for adults. Int J Behav Nutr Phys Act, 7, 2010, 39.
139. Shiroma, E.J., Lee, I.M., Physical activity and cardiovascular health: lessons learned from epidemiological studies across age, gender, and race/ethnicity. Circulation 122 (2010), 743–752.
140. Sattelmair, J., Pertman, J., Ding, E.L., et al. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation 124 (2011), 789–795.
141. American College of Cardiology. ASCVD Risk Predictor Plus. Available at: http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/. Accessed September 1, 2018.
142. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
143. Yusuf, S., Bosch, J., Dagenais, G., et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374 (2016), 2021–2031.
144. Baigent, C., Blackwell, L., Emberson, J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
145. Baigent, C., Landray, M.J., Reith, C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377 (2011), 2181–2192.
146. Cholesterol Treatment Trialists C Herrington, W.G., Emberson, J., et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 4 (2016), 829–839.
147. Chou, R., Dana, T., Blazina, I., et al. Statin use for the prevention of cardiovascular disease in adults: a systematic review for the U.S. Preventive Services Task Force. 2016, U.S. Agency for Healthcare Research and Quality, Rockville, MD Report No.: 14-05206-EF-2.
148. Downs, J.R., Clearfield, M., Weis, S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998), 1615–1622.
149. Ridker, P.M., Danielson, E., Fonseca, F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008), 2195–2207.
150. Taylor, F., Huffman, M.D., Macedo, A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev, 2013, CD004816.
151. Yusuf, S., Bosch, J., Dagenais, G., et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 374 (2016), 2021–2031.
152. Silverman, M.G., Ference, B.A., Im, K., et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 316 (2016), 1289–1297.
153. Karmali, K.N., Goff, D.C. Jr, Ning, H., et al. A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol 64 (2014), 959–968.
154. Muntner, P., Colantonio, L.D., Cushman, M., et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA 311 (2014), 1406–1415.
155. Krumholz, H.M., Treatment of cholesterol in 2017. JAMA 318 (2017), 417–418.
156. Martin, S.S., Sperling, L.S., Blaha, M.J., et al. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines. J Am Coll Cardiol 65 (2015), 1361–1368.
157. Stacey, D., Legare, F., Lewis, K., et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev, 4, 2017, CD001431.
158. Mortensen, M.B., Fuster, V., Muntendam, P., et al. A simple disease-guided approach to personalize ACC/AHA-recommended statin allocation in elderly people: the BioImage study. J Am Coll Cardiol 68 (2016), 881–891.
159. Willeit, P., Kiechl, S., Kronenberg, F., et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol 64 (2014), 851–860.
160. Nasir, K., Bittencourt, M.S., Blaha, M.J., et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 66 (2015), 1657–1668.
161. Ridker, P.M., Mora, S., Rose, L., Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J 37 (2016), 1373–1379.
162. Yano, Y., O'Donnell, C.J., Kuller, L., et al. Association of coronary artery calcium score vs age with cardiovascular risk in older adults: an analysis of pooled population-based studies. JAMA Cardiol 2 (2017), 986–994.
163. Malik, S., Zhao, Y., Budoff, M., et al. Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the Multi-Ethnic Study of Atherosclerosis. JAMA Cardiol 2 (2017), 1332–1340.
164. Sniderman, A.D., Tsimikas, S., Fazio, S., The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. J Am Coll Cardiol 63 (2014), 1935–1947.
165. Sniderman, A.D., Williams, K., Contois, J.H., et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 4 (2011), 337–345.
166. Budoff, M.J., Young, R., Burke, G., et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). Eur Heart J 39 (2018), 2401–2408.
167. Mihaylova, B., Emberson, J., Blackwell, L., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380 (2012), 581–590.
168. Miller, M., Stone, N.J., Ballantyne, C., et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123 (2011), 2292–2333.
169. Benner, J.S., Tierce, J.C., Ballantyne, C.M., et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 22:suppl 3 (2004), 13–23.
170. Miller, M., Stone, N.J., Ballantyne, C., et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123 (2011), 2292–2333.
171. Benner, J.S., Tierce, J.C., Ballantyne, C.M., et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 22:suppl 3 (2004), 13–23.
172. Chiavaroli, L., Nishi, S.K., Khan, T.A., et al. Portfolio dietary pattern and cardiovascular disease: a systematic review and meta-analysis of controlled trials. Prog Cardiovasc Dis 61 (2018), 43–53.
173. Glynn, R.J., Koenig, W., Nordestgaard, B.G., et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 152 (2010), 488–496 w174.
174. Ridker, P.M., Danielson, E., Fonseca, F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008), 2195–2207.
175. Ridker, P.M., Lonn, E., Paynter, N.P., et al. Primary prevention with statin therapy in the elderly: new meta-analyses from the Contemporary JUPITER and HOPE-3 Randomized Trials. Circulation 135 (2017), 1979–1981.
176. Yusuf, S., Bosch, J., Dagenais, G., et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374 (2016), 2021–2031.
177. Orkaby, A.R., Gaziano, J.M., Djousse, L., et al. Statins for primary prevention of cardiovascular events and mortality in older men. J Am Geriatr Soc 65 (2017), 2362–2368.
178. Mihaylova, B., Emberson, J., Blackwell, L., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380 (2012), 581–590.
179. Savarese, G., Gotto, A.M. Jr, Paolillo, S., et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol 62 (2013), 2090–2099.
180. Teng, M., Lin, L., Zhao, Y.J., et al. Statins for primary prevention of cardiovascular disease in elderly patients: systematic review and meta-analysis. Drugs Aging 32 (2015), 649–661.
181. Kutner, J.S., Blatchford, P.J., Taylor, D.H. Jr, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med 175 (2015), 691–700.
182. Mahabadi, A.A., Mohlenkamp, S., Lehmann, N., et al. CAC score improves coronary and CV risk assessment above statin indication by ESC and AHA/ACC primary prevention guidelines. J Am Coll Cardiol Img 10 (2017), 143–153.
183. Mortensen, M.B., Fuster, V., Muntendam, P., et al. A simple disease-guided approach to personalize ACC/AHA-recommended statin allocation in elderly people: the BioImage study. J Am Coll Cardiol 68 (2016), 881–891.
184. Iannuzzi, A., Licenziati, M.R., Vacca, M., et al. Comparison of two diets of varying glycemic index on carotid subclinical atherosclerosis in obese children. Heart Vessels 24 (2009), 419–424.
185. Murphy, E.C., Carson, L., Neal, W., et al. Effects of an exercise intervention using Dance Dance Revolution on endothelial function and other risk factors in overweight children. Int J Pediatr Obes 4 (2009), 205–214.
186. Pratt, R.E., Kavey, R.E., Quinzi, D., Combined dyslipidemia in obese children: response to a focused lifestyle approach. J Clin Lipidol 8 (2014), 181–186.
187. de Ferranti, S.D., Milliren, C.E., Denhoff, E.R., et al. Providing food to treat adolescents at risk for cardiovascular disease. Obesity (Silver Spring) 23 (2015), 2109–2117.
188. Niinikoski, H., Lagstrom, H., Jokinen, E., et al. Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation 116 (2007), 1032–1040.
189. Obarzanek, E., Kimm, S.Y., Barton, B.A., et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (DISC). Pediatrics 107 (2001), 256–264.
190. Dorgan, J.F., Liu, L., Barton, B.A., et al. Adolescent diet and metabolic syndrome in young women: results of the Dietary Intervention Study in Children (DISC) follow-up study. J Clin Endocrinol Metab 96 (2011), E1999–E2008.
191. Wong, H., Chahal, N., Manlhiot, C., et al. Flaxseed in pediatric hyperlipidemia: a placebo-controlled, blinded, randomized clinical trial of dietary flaxseed supplementation for children and adolescents with hypercholesterolemia. JAMA Pediatr 167 (2013), 708–713.
192. Zachariah, J.P., Chan, J., Mendelson, M.M., et al. Adolescent dyslipidemia and standardized lifestyle modification: benchmarking real-world practice. J Am Coll Cardiol 68 (2016), 2122–2123.
193. Torvik, K., Narverud, I., Ottestad, I., et al. Dietary counseling is associated with an improved lipid profile in children with familial hypercholesterolemia. Atherosclerosis 252 (2016), 21–27.
194. Koletzko, B., Kupke, I., Wendel, U., Treatment of hypercholesterolemia in children and adolescents. Acta Paediatr 81 (1992), 682–685.
195. Tershakovec, A.M., Shannon, B.M., Achterberg, C.L., et al. One-year follow-up of nutrition education for hypercholesterolemic children. Am J Public Health 88 (1998), 258–261.
196. Kusters, D.M., Caceres, M., Coll, M., et al. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. J Pediatr 166 (2015), 1377–1384 e1-3.
197. Yeste, D., Chacon, P., Clemente, M., et al. Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents. J Pediatr Endocrinol Metab 22 (2009), 487–492.
198. Clauss, S., Wai, K.M., Kavey, R.E., et al. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr 154 (2009), 869–872.
199. Sonnett, T., Robinson, J., Milani, P., et al. Role of colesevelam in managing heterozygous familial hypercholesterolemia in adolescents and children. Adolesc Health Med Ther 1 (2010), 53–60.
200. Wald, D.S., Kasturiratne, A., Godoy, A., et al. Child-parent screening for familial hypercholesterolemia. J Pediatr 159 (2011), 865–867.
201. Wald, D.S., Bestwick, J.P., Morris, J.K., et al. Child-parent familial hypercholesterolemia screening in primary care. N Engl J Med 375 (2016), 1628–1637.
202. Ritchie, S.K., Murphy, E.C., Ice, C., et al. Universal versus targeted blood cholesterol screening among youth: the CARDIAC project. Pediatrics 126 (2010), 260–265.
203. Skovby, F., Micic, S., Jepsen, B., et al. Screening for familial hypercholesterolaemia by measurement of apolipoproteins in capillary blood. Arch Dis Child 66 (1991), 844–847.
204. Garcia, R.E., Moodie, D.S., Routine cholesterol surveillance in childhood. Pediatrics 84 (1989), 751–755.
205. Ned, R.M., Sijbrands, E.J., Cascade screening for familial hypercholesterolemia (FH). PLoS Curr, 3, 2011, RRN1238.
206. Bender, R., Bell, D.A., Hooper, A.J., et al. Screening for familial hypercholesterolaemia. Pathology 44 (2012), 122–128.
207. National Institute for Health and Care Excellence (NICE) (UK). Familial hypercholesterolaemia: identification and management. Available at: http://www.nice.org.uk/guidance/CG71. Accessed August 24, 2018.
208. Kit, B.K., Kuklina, E., Carroll, M.D., et al. Prevalence of and trends in dyslipidemia and blood pressure among US children and adolescents, 1999-2012. JAMA Pediatr 169 (2015), 272–279.
209. May, A.L., Kuklina, E.V., Yoon, P.W., Prevalence of cardiovascular disease risk factors among US adolescents, 1999-2008. Pediatrics 129 (2012), 1035–1041.
210. Lozano, P., Henrikson, N.B., Morrison, C.C., et al. Lipid screening in childhood and adolescence for detection of multifactorial dyslipidemia: evidence report and systematic review for the US Preventive Services Task Force. JAMA 316 (2016), 634–644.
211. Gidding, S.S., Champagne, M.A., de Ferranti, S.D., et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation 132 (2015), 2167–2192.
212. Lozano, P., Henrikson, N.B., Dunn, J., et al. Lipid screening in childhood and adolescence for detection of familial hypercholesterolemia: evidence report and systematic review for the US Preventive Services Task Force. JAMA 316 (2016), 645–655.
213. Carnethon, M.R., Pu, J., Howard, G., et al. Cardiovascular health in African Americans: a scientific statement from the American Heart Association. Circulation 136 (2017), e393–e423.
214. Gujral, U.P., Vittinghoff, E., Mongraw-Chaffin, M., et al. Cardiometabolic abnormalities among normal-weight persons from five racial/ethnic groups in the United States: a cross-sectional analysis of two cohort studies. Ann Intern Med 166 (2017), 628–636.
215. Rao, G., Powell-Wiley, T.M., Ancheta, I., et al. Identification of obesity and cardiovascular risk in ethnically and racially diverse populations: a scientific statement from the American Heart Association. Circulation 132 (2015), 457–472.
216. Hata, J., Kiyohara, Y., Epidemiology of stroke and coronary artery disease in Asia. Circ J 77 (2013), 1923–1932.
217. Group H-TC. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 34 (2013), 1279–1291.
218. Feinstein, M.J., Nance, R.M., Drozd, D.R., et al. Assessing and refining myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the Centers for AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol 2 (2017), 155–162.
219. Daviglus, M.L., Pirzada, A., Talavera, G.A., Cardiovascular disease risk factors in the Hispanic/Latino population: lessons from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Prog Cardiovasc Dis 57 (2014), 230–236.
220. Daviglus, M.L., Pirzada, A., Durazo-Arvizu, R., et al. Prevalence of low cardiovascular risk profile among diverse Hispanic/Latino adults in the United States by age, sex, and level of acculturation: the Hispanic Community Health Study/Study of Latinos. J Am Heart Assoc, 5, 2016, e003929.
221. Gonzalez, H.M., Tarraf, W., Rodriguez, C.J., et al. Cardiovascular health among diverse Hispanics/Latinos: Hispanic Community Health Study/Study of Latinos (HCHS/SOL) results. Am Heart J 176 (2016), 134–144.
222. Qureshi, W.T., Kaplan, R.C., Swett, K., et al. American College of Cardiology/American Heart Association (ACC/AHA) Class I guidelines for the treatment of cholesterol to reduce atherosclerotic cardiovascular risk: implications for US Hispanics/Latinos based on findings from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). J Am Heart Assoc, 6, 2017, e005045.
223. Schneiderman, N., Chirinos, D.A., Aviles-Santa, M.L., et al. Challenges in preventing heart disease in hispanics: early lessons learned from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Prog Cardiovasc Dis 57 (2014), 253–261.
224. Hutchinson, R.N., Shin, S., Systematic review of health disparities for cardiovascular diseases and associated factors among American Indian and Alaska Native populations. PLoS One, 9, 2014, e80973.
225. Volgman, A.S., Palaniappan, L.S., Aggarwal, N.T., et al. Atherosclerotic cardiovascular disease in South Asians in the United States: epidemiology, risk factors, and treatments: a scientific statement from the American Heart Association. Circulation 138 (2018), e1–e34.
226. Conomos, M.P., Laurie, C.A., Stilp, A.M., et al. Genetic diversity and association studies in US Hispanic/Latino populations: applications in the Hispanic Community Health Study/Study of Latinos. Am J Hum Genet 98 (2016), 165–184.
227. Frank, A.T., Zhao, B., Jose, P.O., et al. Racial/ethnic differences in dyslipidemia patterns. Circulation 129 (2014), 570–579.
228. Pu, J., Romanelli, R., Zhao, B., et al. Dyslipidemia in special ethnic populations. Cardiol Clin 33 (2015), 325–333.
229. Basu, S., Hong, A., Siddiqi, A., Using decomposition analysis to identify modifiable racial disparities in the distribution of blood pressure in the United States. Am J Epidemiol 182 (2015), 345–353.
230. Ford, E.S., Li, C., Zhao, G., Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes 2 (2010), 180–193.
231. Gujral, U.P., Pradeepa, R., Weber, M.B., et al. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann N Y Acad Sci 1281 (2013), 51–63.
232. Ma, R.C., Chan, J.C., Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci 1281 (2013), 64–91.
233. Menke, A., Casagrande, S., Geiss, L., et al. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA 314 (2015), 1021–1029.
234. DeFilippis, A.P., Young, R., McEvoy, J.W., et al. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. Eur Heart J 38 (2017), 598–608.
235. Goff, D.C. Jr, Lloyd-Jones, D.M., Bennett, G., et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2935–2959.
236. Muntner, P., Colantonio, L.D., Cushman, M., et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA 311 (2014), 1406–1415.
237. Rana, J.S., Tabada, G.H., Solomon, M.D., et al. Accuracy of the atherosclerotic cardiovascular risk equation in a large contemporary, multiethnic population. J Am Coll Cardiol 67 (2016), 2118–2130.
238. Kandula, N.R., Kanaya, A.M., Liu, K., et al. Association of 10-year and lifetime predicted cardiovascular disease risk with subclinical atherosclerosis in South Asians: findings from the Mediators of Atherosclerosis in South Asians Living in America (MASALA) study. J Am Heart Assoc, 3, 2014, e001117.
239. Alluri, K., McEvoy, J.W., Dardari, Z.A., et al. Distribution and burden of newly detected coronary artery calcium: results from the Multi-Ethnic Study of Atherosclerosis. J Cardiovasc Comput Tomogr, 9, 2015 337–344 e1.
240. Cho, Y.K., Jung, C.H., Kang, Y.M., et al. 2013 ACC/AHA cholesterol guideline versus 2004 NCEP ATP III guideline in the prediction of coronary artery calcification progression in a Korean population. J Am Heart Assoc, 5, 2016, e003410.
241. Manolio, T.A., Arnold, A.M., Post, W., et al. Ethnic differences in the relationship of carotid atherosclerosis to coronary calcification: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 197 (2008), 132–138.
242. Osawa, K., Nakanishi, R., Budoff, M., Coronary artery calcification. Glob Heart 11 (2016), 287–293.
243. Kanaya, A.M., Kandula, N.R., Ewing, S.K., et al. Comparing coronary artery calcium among U.S. South Asians with four racial/ethnic groups: the MASALA and MESA studies. Atherosclerosis 234 (2014), 102–107.
244. Greenland, P., Blaha, M.J., Budoff, M.J., et al. Coronary calcium score and cardiovascular risk. J Am Coll Cardiol 72 (2018), 434–447.
245. Nakamura, H., Arakawa, K., Itakura, H., et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368 (2006), 1155–1163.
246. Kimura, T., Inoue, T., Taguchi, I., et al. Does high-intensity pitavastatin therapy further improve clinical outcomes? The REAL-CAD study in 13,054 patients with stable coronary artery disease. Circulation, 136, 2017, e450.
247. Birmingham, B.K., Bujac, S.R., Elsby, R., et al. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol 71 (2015), 329–340.
248. Lee, E., Ryan, S., Birmingham, B., et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78 (2005), 330–341.
249. Liao, J.K., Safety and efficacy of statins in Asians. Am J Cardiol 99 (2007), 410–414.
250. Lloret, R., Ycas, J., Stein, M., et al. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). Am J Cardiol 98 (2006), 768–773.
251. George, M.D., McGill, N.K., Baker, J.F., Creatine kinase in the U.S. population: Impact of demographics, comorbidities, and body composition on the normal range. Medicine (Baltimore), 95, 2016, e4344.
252. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
253. Hokanson, J.E., Austin, M.A., Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3 (1996), 213–219.
254. Nordestgaard, B.G., Benn, M., Schnohr, P., et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298 (2007), 299–308.
255. Freiberg, J.J., Tybjaerg-Hansen, A., Jensen, J.S., et al. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 300 (2008), 2142–2152.
256. Karlson, B.W., Palmer, M.K., Nicholls, S.J., et al. A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia. Am J Cardiol 117 (2016), 1444–1448.
257. Cholesterol Treatment Trialists C Mihaylova, B., Emberson, J., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380 (2012), 581–590.
258. Christian, J.B., Arondekar, B., Buysman, E.K., et al. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. J Clin Lipidol 6 (2012), 450–461.
259. Duane, W.C., Hunninghake, D.B., Freeman, M.L., et al. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology 8 (1988), 1147–1150.
260. Rhodes, K.S., Weintraub, M., Marchlewicz, E.H., et al. Medical nutrition therapy is the essential cornerstone for effective treatment of “refractory” severe hypertriglyceridemia regardless of pharmaceutical treatment: Evidence from a Lipid Management Program. J Clin Lipidol 9 (2015), 559–567.
261. Ouyang, P., Wenger, N.K., Taylor, D., et al. Strategies and methods to study female-specific cardiovascular health and disease: a guide for clinical scientists. Biol Sex Differ, 7, 2016, 19.
262. Grandi, S.M., Vallee-Pouliot, K., Reynier, P., et al. Hypertensive disorders in pregnancy and the risk of subsequent cardiovascular disease. Paediatr Perinat Epidemiol 31 (2017), 412–421.
263. Shostrom, D.C.V., Sun, Y., Oleson, J.J., et al. History of gestational diabetes mellitus in relation to cardiovascular disease and cardiovascular risk factors in US women. Front Endocrinol (Lausanne), 8, 2017, 144.
264. Catov, J.M., Newman, A.B., Roberts, J.M., et al. Preterm delivery and later maternal cardiovascular disease risk. Epidemiology 18 (2007), 733–739.
265. Muka, T., Oliver-Williams, C., Kunutsor, S., et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol 1 (2016), 767–776.
266. Roeters van Lennep, J.E., Heida, K.Y., Bots, M.L., et al. Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta-analysis. Eur J Prev Cardiol 23 (2016), 178–186.
267. Edison, R.J., Muenke, M., Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med 350 (2004), 1579–1582.
268. Ofori, B., Rey, E., Berard, A., Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol 64 (2007), 496–509.
269. Taguchi, N., Rubin, E.T., Hosokawa, A., et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol 26 (2008), 175–177.
270. Winterfeld, U., Allignol, A., Panchaud, A., et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG 120 (2013), 463–471.
271. Zarek, J., Koren, G., The fetal safety of statins: a systematic review and meta-analysis. J Obstet Gynaecol Can 36 (2014), 506–509.
272. McGrogan, A., Snowball, J., Charlton, R.A., Statins during pregnancy: a cohort study using the General Practice Research Database to investigate pregnancy loss. Pharmacoepidemiol Drug Saf 26 (2017), 843–852.
273. Cholesterol Treatment Trialists’ (CTT) Collaboration Herrington, W., Emberson, J., et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 4 (2016), 829–839.
274. Baigent, C., Landray, M.J., Reith, C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377 (2011), 2181–2192.
275. Fellstrom, B.C., Jardine, A.G., Schmieder, R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 (2009), 1395–1407.
276. Wanner, C., Krane, V., Marz, W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005), 238–248.
277. Mantel, A., Holmqvist, M., Jernberg, T., et al. Rheumatoid arthritis is associated with a more severe presentation of acute coronary syndrome and worse short-term outcome. Eur Heart J 36 (2015), 3413–3422.
278. Douglas, K.M., Pace, A.V., Treharne, G.J., et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis 65 (2006), 348–353.
279. Lindhardsen, J., Ahlehoff, O., Gislason, G.H., et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 70 (2011), 929–934.
280. Avina-Zubieta, J.A., Choi, H.K., Sadatsafavi, M., et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59 (2008), 1690–1697.
281. Wajed, J., Ahmad, Y., Durrington, P.N., et al. Prevention of cardiovascular disease in systemic lupus erythematosus—proposed guidelines for risk factor management. Rheumatology (Oxford) 43 (2004), 7–12.
282. Westerweel, P.E., Luyten, R.K., Koomans, H.A., et al. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 56 (2007), 1384–1396.
283. Mehta, N.N., Azfar, R.S., Shin, D.B., et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 31 (2010), 1000–1006.
284. Hanna, D.B., Ramaswamy, C., Kaplan, R.C., et al. Trends in cardiovascular disease mortality among persons with HIV in New York City, 2001-2012. Clin Infect Dis 63 (2016), 1122–1129.
285. Triant, V.A., Lee, H., Hadigan, C., et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 92 (2007), 2506–2512.
286. Kearns, A., Gordon, J., Burdo, T.H., et al. HIV-1-associated atherosclerosis: unraveling the missing link. J Am Coll Cardiol 69 (2017), 3084–3098.
287. Dregan, A., Chowienczyk, P., Molokhia, M., Cardiovascular and type 2 diabetes morbidity and all-cause mortality among diverse chronic inflammatory disorders. Heart 103 (2017), 1867–1873.
288. Fernandez-Montero, J.V., Barreiro, P., de Mendoza, C., et al. Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients. J Viral Hepat 23 (2016), 47–52.
289. Bartels, C.M., Kind, A.J., Everett, C., et al. Low frequency of primary lipid screening among medicare patients with rheumatoid arthritis. Arthritis Rheum 63 (2011), 1221–1230.
290. Toms, T.E., Panoulas, V.F., Douglas, K.M., et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?. Ann Rheum Dis 69 (2010), 683–688.
291. Friis-Moller, N., Sabin, C.A., Weber, R., et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 (2003), 1993–2003.
292. Feinstein, M.J., Nance, R.M., Drozd, D.R., et al. Assessing and refining myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the Centers for AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol 2 (2017), 155–162.
293. Arts, E.E., Popa, C., Den Broeder, A.A., et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis 74 (2015), 668–674.
294. Mulligan, K., Grunfeld, C., Tai, V.W., et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 23 (2000), 35–43.
295. Ledergerber, B., Furrer, H., Rickenbach, M., et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 45 (2007), 111–119.
296. Davis, J.M. 3rd, Maradit Kremers, H., Crowson, C.S., et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 56 (2007), 820–830.
297. Myasoedova, E., Crowson, C.S., Kremers, H.M., et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 70 (2011), 482–487.
298. Ronda, N., Favari, E., Borghi, M.O., et al. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 73 (2014), 609–615.
299. Navarro-Millan, I., Charles-Schoeman, C., Yang, S., et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum 65 (2013), 1430–1438.
300. Taylor, F., Huffman, M.D., Macedo, A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev, 2013, CD004816.
301. Martin, S.S., Sperling, L.S., Blaha, M.J., et al. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines. J Am Coll Cardiol 65 (2015), 1361–1368.
302. Parker, B.A., Capizzi, J.A., Grimaldi, A.S., et al. Effect of statins on skeletal muscle function. Circulation 127 (2013), 96–103.
303. Gupta, A., Thompson, D., Whitehouse, A., et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 389 (2017), 2473–2481.
304. Nissen, S.E., Stroes, E., Dent-Acosta, R.E., et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA 315 (2016), 1580–1590.
305. Moriarty, P.M., Thompson, P.D., Cannon, C.P., et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol 9 (2015), 758–769.
306. Joy, T.R., Monjed, A., Zou, G.Y., et al. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med 160 (2014), 301–310.
307. Ridker, P.M., Pradhan, A., MacFadyen, J.G., et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380 (2012), 565–571.
308. Preiss, D., Seshasai, S.R., Welsh, P., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305 (2011), 2556–2564.
309. Sattar, N., Preiss, D., Murray, H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375 (2010), 735–742.
310. Navarese, E.P., Buffon, A., Andreotti, F., et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 111 (2013), 1123–1130.
311. Knowler, W.C., Barrett-Connor, E., Fowler, S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002), 393–403.
312. Stroes, E.S., Thompson, P.D., Corsini, A., et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 36 (2015), 1012–1022.
313. Thompson, P.D., Panza, G., Zaleski, A., et al. Statin-Associated Side Effects. J Am Coll Cardiol 67 (2016), 2395–2410.
314. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
315. Athyros, V.G., Tziomalos, K., Gossios, T.D., et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 376 (2010), 1916–1922.
316. Foster, T., Budoff, M.J., Saab, S., et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 106 (2011), 71–77.
317. Tikkanen, M.J., Fayyad, R., Faergeman, O., et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 168 (2013), 3846–3852.
318. Lloyd-Jones, D.M., Morris, P.B., Ballantyne, C.M., et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 68 (2016), 92–125.
319. Taylor, B.A., Lorson, L., White, C.M., et al. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis 238 (2015), 329–335.
320. Banach, M., Serban, C., Sahebkar, A., et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc 90 (2015), 24–34.
321. Baigent, C., Blackwell, L., Emberson, J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
322. Collins, R., Reith, C., Emberson, J., et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388 (2016), 2532–2561.
323. Yusuf, S., Bosch, J., Dagenais, G., et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374 (2016), 2021–2031.
324. Bruckert, E., Hayem, G., Dejager, S., et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther 19 (2005), 403–414.
325. Cohen, J.D., Brinton, E.A., Ito, M.K., et al. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 6 (2012), 208–215.
326. Serban, M.C., Colantonio, L.D., Manthripragada, A.D., et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol 69 (2017), 1386–1395.
327. Zhang, H., Plutzky, J., Shubina, M., et al. Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study. Ann Intern Med 167 (2017), 221–227.
328. Zhang, H., Plutzky, J., Skentzos, S., et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 158 (2013), 526–534.
329. Brown, B.G., Bardsley, J., Poulin, D., et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol 80 (1997), 111–115.
330. Tamblyn, R., Reidel, K., Huang, A., et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Med Decis Making 30 (2010), 176–188.
331. Thom, S., Poulter, N., Field, J., et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 310 (2013), 918–929.
332. van Driel, M.L., Morledge, M.D., Ulep, R., et al. Interventions to improve adherence to lipid-lowering medication. Cochrane Database Syst Rev, 12, 2016, CD004371.
333. Chan, W.V., Pearson, T.A., Bennett, G.C., et al. ACC/AHA special report: clinical practice guideline implementation strategies: a summary of systematic reviews by the NHLBI Implementation Science Work Group: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 69 (2017), 1076–1092.
334. Fischer, F., Lange, K., Klose, K., et al. Barriers and strategies in guideline implementation-a scoping review. Healthcare (Basel), 4, 2016.
335. Stacey, D., Hill, S., McCaffery, K., et al. Shared decision making interventions: theoretical and empirical evidence with implications for health literacy. Stud Health Technol Inform 240 (2017), 263–283.
336. Stacey, D., Legare, F., Lewis, K., et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev, 4, 2017, CD001431.
337. Anderson, J.L., Heidenreich, P.A., Barnett, P.G., et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation 129 (2014), 2329–2345.
338. Sabatine, M.S., Giugliano, R.P., Keech, A.C., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376 (2017), 1713–1722.
339. Hlatky, M.A., Kazi, D.S., PCSK9 inhibitors: economics and policy. J Am Coll Cardiol 70 (2017), 2677–2687.
340. Baigent, C., Keech, A., Kearney, P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005), 1267–1278.
341. Fonarow, G.C., Keech, A.C., Pedersen, T.R., et al. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol 2 (2017), 1069–1078.
342. Robinson, J.G., Huijgen, R., Ray, K., et al. Determining when to add nonstatin therapy: a quantitative approach. J Am Coll Cardiol 68 (2016), 2412–2421.
343. Kazi, D.S., Moran, A.E., Coxson, P.G., et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA 316 (2016), 743–753.
344. Gandra, S.R., Villa, G., Fonarow, G.C., et al. Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol 39 (2016), 313–320.
345. Choosing interventions that are cost effective (WHO-CHOICE): cost-effectiveness thresholds, 2009, World Health Organization, Geneva, Switzerland.
346. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.